These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 18402516

  • 1. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
    Zhu AX.
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
    [No Abstract] [Full Text] [Related]

  • 2. [Targeted HCC therapies: the door has been opened!].
    Rosmorduc O, Fartoux L.
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):1-2. PubMed ID: 18341969
    [No Abstract] [Full Text] [Related]

  • 3. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
    Lang A, Graeven U.
    Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236
    [No Abstract] [Full Text] [Related]

  • 4. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V, Barbare JC, Rosmorduc O, Groupe de travail carcinome hépatocellulaire Prodige-Afef.
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract] [Full Text] [Related]

  • 5. Targeted therapy of hepatocellular cancer.
    Wysocki PJ.
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [Abstract] [Full Text] [Related]

  • 6. Targeting vessels to treat hepatocellular carcinoma.
    Romanque P, Piguet AC, Dufour JF.
    Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
    [Abstract] [Full Text] [Related]

  • 7. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Apr; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 8. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T, Pang R, Chan P, Poon RT.
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [Abstract] [Full Text] [Related]

  • 9. Latest developments in targeted therapy for hepatocellular carcinoma.
    Montella L, Addeo R, Caraglia M, Del Prete S.
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1635-46. PubMed ID: 20942634
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
    Kuzuya T, Tsuchiya K, Izumi N.
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1883-86. PubMed ID: 21069944
    [No Abstract] [Full Text] [Related]

  • 11. Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
    Cipriani G, Mazzanti R.
    Dig Liver Dis; 2005 Apr; 37(4):230-1. PubMed ID: 15788205
    [No Abstract] [Full Text] [Related]

  • 12. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
    Mross K.
    Pharm Unserer Zeit; 2008 Apr; 37(5):404-15. PubMed ID: 18729270
    [No Abstract] [Full Text] [Related]

  • 13. Targeted therapies for hepatocellular carcinoma.
    Skelton MR, O'Neil B.
    Clin Adv Hematol Oncol; 2008 Mar; 6(3):209-18. PubMed ID: 18391920
    [Abstract] [Full Text] [Related]

  • 14. Targeted therapies and non-small-cell lung cancer: new developments.
    Gridelli C.
    Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
    [No Abstract] [Full Text] [Related]

  • 15. Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?
    Montella L, Palmieri G, Addeo R, Del Prete S.
    World J Gastroenterol; 2016 Jul 21; 22(27):6114-26. PubMed ID: 27468204
    [Abstract] [Full Text] [Related]

  • 16. Angiogenesis blockade as therapy for hepatocellular carcinoma: progress and challenges.
    Hao CY.
    J Gastroenterol Hepatol; 2011 Jan 21; 26(1):4-6. PubMed ID: 21175786
    [No Abstract] [Full Text] [Related]

  • 17. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF, Blum HE, Geissler M.
    Dtsch Med Wochenschr; 2005 May 27; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract] [Full Text] [Related]

  • 18. The role of tyrosine kinase inhibitors in hepatocellular carcinoma.
    Kim S, Abou-Alfa GK.
    Clin Adv Hematol Oncol; 2014 Jan 27; 12(1):36-41. PubMed ID: 25000314
    [Abstract] [Full Text] [Related]

  • 19. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
    Zender L, Kubicka S.
    Onkologie; 2008 Oct 27; 31(10):550-5. PubMed ID: 18854656
    [Abstract] [Full Text] [Related]

  • 20. [Insulin-like growth factor (IGF)-signalling pathway components are potential therapeutic targets in the treatment of human hepatocellular carcinoma].
    Nussbaum T, Samarin J, Schirmacher P, Breuhahn K.
    Verh Dtsch Ges Pathol; 2007 Oct 27; 91():278-85. PubMed ID: 18314625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.